Notably, conventional αβ T cells serve as the foundation for six FDA approved CAR-engineered cell products, with applications targeting CD19 for the treatment of B cell malignancies and B-cell maturation antigen (BCMA) for multiple myeloma. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.